Inhaled ciclesonide in adults hospitalised with COVID-19: a randomised controlled open-label trial (HALT COVID-19).

ABSTRACT:

Objective

To assess the efficacy of inhaled ciclesonide in reducing the duration of oxygen therapy (an indicator of time to clinical improvement) among adults hospitalised with COVID-19.

Design

Multicentre, randomised, controlled, open-label trial.

Setting

9 hospitals (3 academic hospitals and 6 non-academic hospitals) in Sweden between 1 June 2020 and 17 May 2021.

Participants

Adults hospitalised with COVID-19 and receiving oxygen therapy.

Intervention

Inhaled ciclesonide 320 µg two times a day for 14 days versus standard care.

Main outcome measures

Primary outcome was duration of oxygen therapy, an indicator of time to clinical improvement. Key secondary outcome was a composite of invasive mechanical ventilation/death.

Results

Data from 9

SUBMITTER: Brodin D 

PROVIDER: S-EPMC9950582 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature